Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD.

Respir Med. 2018 Jun;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

PMID:
29858005
2.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May.

PMID:
29773608
3.

Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis.

Jacob J, Odink A, Brun AL, Macaluso C, de Lauretis A, Kokosi M, Devaraj A, Desai S, Renzoni E, Wells AU.

Respir Med. 2018 May;138:95-101. doi: 10.1016/j.rmed.2018.03.031. Epub 2018 Mar 30.

4.

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.

Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU.

Respir Med. 2018 May;138:13-20. doi: 10.1016/j.rmed.2018.03.019. Epub 2018 Mar 16.

5.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated CT Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Apr 23. doi: 10.1164/rccm.201711-2174OC. [Epub ahead of print]

PMID:
29684284
6.

Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.

Kokosi MA, Margaritopoulos GA, Wells AU.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 170117. doi: 10.1183/16000617.0117-2017. Print 2018 Jun 30.

7.

Pulmonary sarcoidosis.

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU.

Lancet Respir Med. 2018 May;6(5):389-402. doi: 10.1016/S2213-2600(18)30064-X. Epub 2018 Apr 3. Review.

PMID:
29625772
8.

Rapidly Progressive Cystic Lung Disease.

Rogers C, Kent-Bramer J, Devaraj A, Nicholson AG, Molyneaux PL, Wells AU, Saikia S, Maher TM, George PM.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201801-0161IM. [Epub ahead of print] No abstract available.

PMID:
29625015
9.

Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases: A Retrospective Observational Study of 938 Cases.

De Sadeleer LJ, Meert C, Yserbyt J, Slabbynck H, Verschakelen JA, Verbeken EK, Weynand B, De Langhe E, Lenaerts JL, Nemery B, Van Raemdonck D, Verleden GM, Wells AU, Wuyts WA.

Chest. 2018 Jun;153(6):1416-1423. doi: 10.1016/j.chest.2018.03.026. Epub 2018 Mar 30.

PMID:
29608882
10.

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease.

Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU.

EBioMedicine. 2018 Feb;28:303-310. doi: 10.1016/j.ebiom.2018.01.038. Epub 2018 Jan 31.

11.

Validation of multidisciplinary diagnosis in IPF.

Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, Richeldi L, Vancheri C, Wells AU; ERICE ILD working group.

Lancet Respir Med. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7. No abstract available.

PMID:
29413085
12.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

PMID:
29327393
13.

Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy.

George PM, Wells AU.

Expert Rev Clin Immunol. 2018 Feb;14(2):127-135. doi: 10.1080/1744666X.2018.1427064. Epub 2018 Jan 20.

PMID:
29320306
14.

Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure.

Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V.

Respiration. 2018;95(3):188-200. doi: 10.1159/000484055. Epub 2018 Jan 9.

15.

Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis.

Samara KD, Trachalaki A, Tsitoura E, Koutsopoulos AV, Lagoudaki ED, Lasithiotaki I, Margaritopoulos G, Pantelidis P, Bibaki E, Siafakas NM, Tzanakis N, Wells AU, Antoniou KM.

Respir Res. 2017 Dec 29;18(1):218. doi: 10.1186/s12931-017-0692-9.

16.

Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.

Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU.

Respirology. 2018 Jun;23(6):593-599. doi: 10.1111/resp.13231. Epub 2017 Dec 13.

17.

Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.

Jacob J, Bartholmai BJ, Rajagopalan S, Egashira R, Brun AL, Kokosi M, Nair A, Walsh SLF, Karwoski R, Nicholson AG, Hansell DM, Wells AU.

Respir Med. 2017 Sep;130:43-51. doi: 10.1016/j.rmed.2017.07.007. Epub 2017 Jul 14.

PMID:
29206632
18.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

PMID:
29154106
19.

Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease.

Johnson MJ, Jamali A, Ross J, Fairhurst C, Boland J, Reigada C, Hart SP, Grande G, Currow DC, Wells AU, Bajwah S, Papadopoulos T, Bland JM, Yorke J.

Thorax. 2017 Nov 17. pii: thoraxjnl-2017-210911. doi: 10.1136/thoraxjnl-2017-210911. [Epub ahead of print]

20.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

PMID:
29150411
21.

The Genomic Detection of Usual Interstitial Pneumonia from Transbronchial Biopsy Tissue: A Dress Rehearsal for the Future?

Wells AU, Antoniou KM.

Ann Am Thorac Soc. 2017 Nov;14(11):1632-1633. doi: 10.1513/AnnalsATS.201708-670ED. No abstract available.

PMID:
29090993
22.

Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail.

Wells AU, Antoniou KM.

Respirology. 2018 Mar;23(3):244-245. doi: 10.1111/resp.13182. Epub 2017 Oct 20. No abstract available.

23.

Idiopathic pulmonary fibrosis.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.

Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review.

PMID:
29052582
24.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

25.

Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Karwoski R, Wells AU.

Eur Radiol. 2018 Mar;28(3):1318-1327. doi: 10.1007/s00330-017-5053-z. Epub 2017 Sep 29.

PMID:
28963678
26.

POINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? Yes.

Wells AU, Kokosi MA.

Chest. 2017 Nov;152(5):917-919. doi: 10.1016/j.chest.2017.08.1173. Epub 2017 Sep 21. No abstract available.

PMID:
28943282
27.

Rebuttal From Drs Wells and Kokosi.

Wells AU, Kokosi MA.

Chest. 2017 Nov;152(5):922-923. doi: 10.1016/j.chest.2017.08.1176. Epub 2017 Sep 21. No abstract available.

PMID:
28943277
28.

Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival.

Khiroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, Maher TM, Devaraj A, Rice A, Renzoni EA, Nicholson AG.

Am J Surg Pathol. 2017 Dec;41(12):1683-1689. doi: 10.1097/PAS.0000000000000928.

PMID:
28877057
29.

Evaluation of visual and computer-based CT analysis for the identification of functional patterns of obstruction and restriction in hypersensitivity pneumonitis.

Jacob J, Bartholmai BJ, Brun AL, Egashira R, Rajagopalan S, Karwoski R, Kouranos V, Kokosi M, Hansell DM, Wells AU.

Respirology. 2017 Nov;22(8):1585-1591. doi: 10.1111/resp.13122. Epub 2017 Jul 11.

PMID:
28699237
30.

Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700379. doi: 10.1183/13993003.00379-2017. Print 2017 Jul.

PMID:
28679612
31.

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group.

Lancet Respir Med. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9. Review.

PMID:
28664861
32.

Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis.

Cottin V, Hansell DM, Sverzellati N, Weycker D, Antoniou KM, Atwood M, Oster G, Kirchgaessler KU, Collard HR, Wells AU.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1162-1171. doi: 10.1164/rccm.201612-2492OC.

PMID:
28657784
33.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

34.

Update in Interstitial Lung Disease 2016.

Wells AU, Maher TM.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):132-138. doi: 10.1164/rccm.201702-0351UP. No abstract available.

35.

Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis.

Jacob J, Bartholmai BJ, Egashira R, Brun AL, Rajagopalan S, Karwoski R, Kokosi M, Hansell DM, Wells AU.

BMC Pulm Med. 2017 May 4;17(1):81. doi: 10.1186/s12890-017-0418-2.

36.

Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA.

Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.

37.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

PMID:
28426895
38.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP. No abstract available.

PMID:
28414524
39.

Unclassifiable interstitial lung diseases: Clinical characteristics and survival.

Hyldgaard C, Bendstrup E, Wells AU, Hilberg O.

Respirology. 2017 Apr;22(3):494-500. doi: 10.1111/resp.12931. Epub 2016 Nov 6.

PMID:
28297158
40.

Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

George PM, Wells AU.

Expert Rev Clin Pharmacol. 2017 May;10(5):483-491. doi: 10.1080/17512433.2017.1295846. Epub 2017 Mar 7. Review.

PMID:
28266906
41.

Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications.

Ravaglia C, Wells AU, Tomassetti S, Dubini A, Cavazza A, Piciucchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V.

Respiration. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.

42.

Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?

Jacob J, Nicholson AG, Wells AU, Hansell DM.

Eur Respir J. 2017 Feb 23;49(2). pii: 1602524. doi: 10.1183/13993003.02524-2016. Print 2017 Feb. No abstract available.

PMID:
28232420
43.

Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations.

Egashira R, Jacob J, Kokosi MA, Brun AL, Rice A, Nicholson AG, Wells AU, Hansell DM.

Radiology. 2017 Jul;284(1):255-263. doi: 10.1148/radiol.2017152419. Epub 2017 Feb 9.

PMID:
28182861
44.

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis.

Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WO, Moffatt MF, Kim DS, Maher TM.

Respir Res. 2017 Feb 1;18(1):29. doi: 10.1186/s12931-017-0511-3.

45.

Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis.

Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Mak SM, Mok W, Della Casa G, Sugino K, Walsh SLF, Wells AU, Hansell DM.

Eur Radiol. 2017 Sep;27(9):3635-3646. doi: 10.1007/s00330-016-4697-4. Epub 2017 Jan 27.

PMID:
28130610
46.

Proteomic Analysis of Kveim Reagent Identifies Targets of Cellular Immunity in Sarcoidosis.

Eberhardt C, Thillai M, Parker R, Siddiqui N, Potiphar L, Goldin R, Timms JF, Wells AU, Kon OM, Wickremasinghe M, Mitchell D, Weeks ME, Lalvani A.

PLoS One. 2017 Jan 23;12(1):e0170285. doi: 10.1371/journal.pone.0170285. eCollection 2017.

47.

Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.

Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, Blanchard A, Edwards LM, Stock C, Daccord C, Renzoni EA, Wells AU, Moffatt MF, Cookson WOC, Maher TM.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1640-1650. doi: 10.1164/rccm.201607-1408OC.

48.

Comorbidities in interstitial lung diseases.

Margaritopoulos GA, Antoniou KM, Wells AU.

Eur Respir Rev. 2017 Jan 3;26(143). pii: 160027. doi: 10.1183/16000617.0027-2016. Print 2017 Jan. Review.

49.

Subclinical Interstitial Lung Abnormalities: Toward the Early Detection of Idiopathic Pulmonary Fibrosis?

Wells AU, Kokosi MA.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1445-1446. No abstract available.

50.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG.

Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7.

PMID:
27939076

Supplemental Content

Loading ...
Support Center